JAPANESE MARKET

Sun Pharma announces the launch of ILUMYA(tildrakizumab) in Japan

​ILUMYA is a humanized lgG1/k monoclonal antibody designed to selectively bind to the p19 subunit of IL-23 and inhibit its interaction with the IL-23 receptor